Patents by Inventor Johanna Ivaska

Johanna Ivaska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPY OF RAS-DEPENDENT CANCERS
    Publication number: 20230073368
    Abstract: This invention relates to the field of cancer therapeutics. More specifically, the invention relates to inhibiting agents and methods that interfere with RAS-pathway and to their use in treating cancers.
    Type: Application
    Filed: February 11, 2021
    Publication date: March 9, 2023
    Inventors: Johanna LILJA, Johanna IVASKA, Olli PENTIKÄINEN, Sanna NIINIVEHMAS
  • Treatment of HER2-Dependent Cancers by SORL1 Inhibition
    Publication number: 20190169620
    Abstract: This disclosure relates to the field of cancer therapeutics. Exemplary embodiments relate to agents that inhibit expression of SORL1, a gene encoding for Sortilin related protein family-A (SORLA) or the function of SORLA protein, a multifunctional protein belonging to sortilin and LDL-receptor families, and to methods for their use in treating HER2-dependent cancers.
    Type: Application
    Filed: September 28, 2018
    Publication date: June 6, 2019
    Applicant: TURUN YLIOPISTO
    Inventors: Mika PIETILÄ, Johanna IVASKA, Pranshu SAHGAL
  • METHOD FOR INHIBITING OR STIMULATING ANGIOGENESIS IN AN INDIVIDUAL
    Publication number: 20100160228
    Abstract: The invention concerns a method for inhibiting vascular endothelial growth factor receptor 2 (VEGFR2) signalling in an individual by administering an effective amount of an agent capable of activating T cell protein tyrosine phosphatase (TCPTP), and a method for inhibiting angiogenesis and treating or preventing diseases related thereto. Furthermore, this invention concerns a method for stimulating angiogenesis or for treatment or prevention of a disease benefiting from increasing the growth of blood vessels in an individual by inhibiting TCPTP.
    Type: Application
    Filed: May 13, 2008
    Publication date: June 24, 2010
    Applicant: VALTION TEKNILLINEN TUTKIMUSKESKUS
    Inventors: Johanna Ivaska, Elina Mattila
  • Method for activating T cell protein tyrosine phosphatase for therapeutic applications
    Patent number: 7687464
    Abstract: This invention relates to methods for activation of T cell protein tyrosine phosphatase (TCPTP) and for inhibiting tyrosine kinase signalling in an individual. The invention concerns a method for preventing or treating a disease or disorder in an individual, wherein said disease or disorder is curable by inhibiting tyrosine kinase signalling, and a method for preventing cancer, or preventing or inhibiting cancer growth, invasion or metastasis in an individual, based on activating T cell protein tyrosine phosphatase (TCPTP). The invention also concerns pharmaceutical compositions useful in the methods.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: March 30, 2010
    Assignee: Valtion Teknillinen Tutkimuskeskus
    Inventors: Johanna Ivaska, Elina Mattila
  • Method for activating T cell protein phosphatase and therapeutical methods based thereon
    Publication number: 20070116673
    Abstract: This invention relates to methods for activation of T cell protein tyrosine phosphatase (TCPTP) and for inhibiting tyrosine kinase signalling in an individual. The invention concerns a method for preventing or treating a disease or disorder in an individual, wherein said disease or disorder is curable by inhibiting tyrosine kinase signalling, and a method for preventing cancer, or preventing or inhibiting cancer growth, invasion or metastasis in an individual, based on activating T cell protein tyrosine phosphatase (TCPTP). The invention also concerns pharmaceutical compositions useful in the methods.
    Type: Application
    Filed: November 20, 2006
    Publication date: May 24, 2007
    Applicant: Valtion Teknillinen Tutkimuskeskus
    Inventors: Johanna Ivaska, Elina Mattila
  • Integrin binding peptide and use thereof
    Patent number: 6096707
    Abstract: Cyclic peptides comprising three colinear amino acids, arginine-lysine-lysine (RKK) are provided that bind to the integrin .alpha.2I domain and are potent inhibitors of its interaction with collagens I and IV and laminin-1. Methods of using such peptides to block integrin function and to inhibit cell migration are also provided.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: August 1, 2000
    Assignee: BioTie Therapies Ltd.
    Inventors: Jyrki Heino, Johanna Ivaska, Jarmo Kapyla